Business Description
Veracyte Inc
NAICS : 541380
SIC : 8734
ISIN : US92337F1075
Total Employee Number:
755Description
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 12.1 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | 0.29 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 8/9 | |||||
Altman Z-Score | 21.65 | |||||
Beneish M-Score | -2.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 15.7 | |||||
3-Year Book Growth Rate | 3.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 20.03 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.96 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.32 | |||||
9-Day RSI | 40.22 | |||||
14-Day RSI | 40.5 | |||||
3-1 Month Momentum % | -0.11 | |||||
6-1 Month Momentum % | 39.5 | |||||
12-1 Month Momentum % | 45.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.16 | |||||
Quick Ratio | 8.8 | |||||
Cash Ratio | 7.73 | |||||
Days Inventory | 50.51 | |||||
Days Sales Outstanding | 32.17 | |||||
Days Payable | 16.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | 0.09 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.71 | |||||
Operating Margin % | 19.34 | |||||
Net Margin % | 20.37 | |||||
EBITDA Margin % | 24.36 | |||||
FCF Margin % | 29.54 | |||||
OCF Margin % | 31.75 | |||||
ROE % | 8.78 | |||||
ROA % | 8.13 | |||||
ROIC % | 11 | |||||
3-Year ROIIC % | 1285.61 | |||||
ROC (Joel Greenblatt) % | 141.41 | |||||
ROCE % | 8.64 | |||||
Years of Profitability over Past 10-Year | 2 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 30.96 | |||||
Forward PE Ratio | 35.28 | |||||
PE Ratio without NRI | 20.79 | |||||
Price-to-Owner-Earnings | 28.24 | |||||
PS Ratio | 6.34 | |||||
PB Ratio | 2.53 | |||||
Price-to-Tangible-Book | 6.51 | |||||
Price-to-Free-Cash-Flow | 21.4 | |||||
Price-to-Operating-Cash-Flow | 19.92 | |||||
EV-to-EBIT | 26.41 | |||||
EV-to-Forward-EBIT | 28.73 | |||||
EV-to-EBITDA | 22.39 | |||||
EV-to-Forward-EBITDA | 16.72 | |||||
EV-to-Revenue | 5.45 | |||||
EV-to-Forward-Revenue | 4.5 | |||||
EV-to-FCF | 18.46 | |||||
Price-to-GF-Value | 1.12 | |||||
Price-to-Projected-FCF | 2.09 | |||||
Price-to-Median-PS-Value | 1.06 | |||||
Price-to-Graham-Number | 2.45 | |||||
| Price-to-Net-Current-Asset-Value | 7.36 | |||||
| Price-to-Net-Cash | 9.06 | |||||
Earnings Yield (Greenblatt) % | 3.79 | |||||
FCF Yield % | 4.73 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VCYT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Veracyte Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 561.9 | ||
| EPS (TTM) ($) | 1.41 | ||
| Beta | 1.9512 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 0.89 | ||
| Volatility % | 67.45 | ||
| 14-Day RSI | 40.5 | ||
| 14-Day ATR ($) | 2.155126 | ||
| 20-Day SMA ($) | 43.1765 | ||
| 12-1 Month Momentum % | 45.47 | ||
| 52-Week Range ($) | 29.455 - 60.91 | ||
| Shares Outstanding (Mil) | 80.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Veracyte Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Veracyte Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 170 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-25 16:30 | In 170 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 169 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 57 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 56 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-15 07:00 | In 7 days | ||
| Canaccord Genuity 46th Annual Growth Conference | 2026-08-11 10:30 | 46.27 (-1.28%) | ||
| Second quarter earnings conference call for 2026 | 2026-07-30 16:30 | 55.71 (-0.57%) | ||
| Second quarter earnings results for 2026 | 2026-07-30 | 55.71 (-0.57%) | ||
| General meeting for 2026 | 2026-06-10 10:00 | 49.24 (+2.60%) |
Show
Entries
Veracyte Inc Frequently Asked Questions
What is Veracyte Inc(VCYT)'s stock price today?
The current price of VCYT is $43.65. The 52 week high of VCYT is $60.91 and 52 week low is $29.46.
When is next earnings date of Veracyte Inc(VCYT)?
The next earnings date of Veracyte Inc(VCYT) is 2026-11-04 Est..
Does Veracyte Inc(VCYT) pay dividends? If so, how much?
Veracyte Inc(VCYT) does not pay dividend.
Guru Commentaries on NAS:VCYT
Artisan Mid Cap Fund
Bearish
2026 Q3
ARTMX APDMX APHMX MCommentary 0726 vR
Artisan Mid Cap Fund
· 60 holdings
What the manager wrote
Veracyte is a molecular diagnostics company focused on genomic testing that helps physicians make more informed treatment decisions and reduce unnecessary procedures. Recent results were mixed, with continued strength in Afirma® offset by a modest Decipher® shortfall following changes to prostate cancer treatment guidelines for low-risk patients. We trimmed the position as questions around Decipher® growth are likely to persist until newer product launches, such as Prosigna®, become more meaningful contributors. We continue to monitor the long-term opportunity.
Press Release
Articles on Veracyte Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers